耗尽的Lag-3+ CD4+ T细胞在儿科炎症性肠病中增加
Alexander Schnell1, Carmen Aicher2, Philipp A Schnegelsberg2
1Pediatric Gastroenterology, Hepatology and Endoscopy, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Bavaria, Germany.
Clinical and experimental immunology
|July 24, 2024
概括
通过分析T细胞概况,可以预测儿科炎症性肠病 (IBD) 治疗因弗利西马布 (IFX) 疗法的成功. 增加的Lag-3+ T细胞表明对IFX治疗的反应不佳.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 儿科 儿科 儿科
背景情况:
- T细胞是炎症性肠病 (IBD) 的关键驱动因素.
- 因弗利西马布 (IFX) 中和TNFα治疗IBD,但预测治疗成功是具有挑战性的.
- 了解T细胞概况可以识别IFX治疗结果的生物标志物.
研究的目的:
- 在儿科IBD患者中确定因弗利西马布 (IFX) 治疗成功的预测生物标志物.
- 在IFX治疗前和治疗期间分析T细胞的化学/主导受体和细胞因子概况.
- 为了区分治疗响应者和不响应者之间的T细胞特征.
主要方法:
- 来自儿科IBD患者的外周血液CD4+T细胞的免疫磁性隔离.
- 细胞分布的流动细胞计分析,化学/本源受体表达 (例如CD62-L,α4β7) 和细胞产生 (例如IFNγ).
- 在IFX治疗前和治疗期间,对21个反应者 (RS) 和21个不反应者 (NRS) 之间的T细胞概况进行比较.
主要成果:
- 与健康对照组相比,儿科IBD患者的T细胞细胞因子概况发生变化,原始T细胞减少.
- IFX治疗导致扩大了响应者和不响应者的记忆和调节性T细胞种群.
- 治疗反应者表现出α4β7+和IFNγ+T细胞的减少,而不响应者表现出Lag-3+T细胞的增加,这表明表型耗尽.
结论:
- 儿科IBDT细胞具有激活的,Th1/Th17转移的表型.
- 增加T细胞上的Lag-3表达是儿童IBDIFX治疗失败的潜在预测生物标志物.
- 准T细胞概况可能会改善个性化的IBD治疗策略.
更多相关视频
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
208
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
208
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Immunodeficiency Diseases
931
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
931
Renewal of Intestinal Stem Cells
2.5K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.5K


